The BTN1A1 Knockout TE1 Polyclonal Cells are a polyclonal CRISPR/Cas9-edited knockout cell population derived from the TE1 human esophageal squamous cell carcinoma line. This product provides a heterogeneous pool of cells harboring targeted disruptions in the BTN1A1 gene, enabling functional loss-of-function studies without the biases of monoclonal selection. Polyclonal populations are particularly advantageous for experiments requiring biological variability that mirrors the heterogeneity of tumor tissues, and for high-throughput screening where broad genetic representation is desired.
The parental TE1 cell line was established from a well-differentiated human esophageal squamous cell carcinoma and carries a mutant TP53 allele, a frequent alteration in esophageal cancer. These adherent epithelial cells are widely used as a model system to investigate malignant phenotypes such as uncontrolled proliferation, migration, and immune evasion. Their robust growth and well-characterized genetic background make them amenable to CRISPR/Cas9 genome editing and subsequent downstream analyses.
BTN1A1 is a butyrophilin family member implicated in immune checkpoint regulation. It is proposed to act as a T-cell inhibitory ligand, delivering negative signals that dampen T-cell receptor (TCR)-mediated activation. Its expression is transcriptionally induced by interferon-gamma through STAT1 and NF-??B. Mechanistically, BTN1A1 interacts with xanthine dehydrogenase (XDH) and the TCR complex, including CD3, LCK, and ZAP70, interfering with proximal phosphorylation events required for full T-cell activation. Additionally, in mammary epithelial cells, BTN1A1 plays a role in lipid droplet formation, indicating tissue-specific functions.
In the context of esophageal squamous cell carcinoma, the TP53-mutant TE1 background provides a clinically relevant platform to study BTN1A1-mediated immune suppression. Knockout of BTN1A1 in this model is expected to relieve inhibition of T-cell responses, potentially synergizing with the pro-inflammatory signals generated by TP53 dysfunction. This system allows researchers to examine how loss of BTN1A1 impacts downstream signaling pathways such as the LCK/ZAP70 axis and XDH function, and to assess changes in the tumor cell secretome that influence T-cell activation and cytotoxicity.
The BTN1A1 Knockout TE1 Polyclonal Cells support a wide range of experimental applications. They can be used in co-culture T-cell activation assays to measure proliferative responses and cytokine production via flow cytometry and ELISA, in migration and invasion assays to evaluate tumor aggressiveness, and in Western blotting to confirm alterations in key signaling nodes. The cells are also suitable for RNA-seq transcriptomic profiling and high-throughput compound screens targeting the tumor-immune interface. For ordering and technical support, please contact Ascent Research.
